Serum levels of morphogenetic proteins (fibroblast growth factor-23 and Klotho): clinical significance


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. Study of clinical significance of serum concentrations of fibroblast growth factor-23 (FGF-23)/Klotho in patients with chronic kidney disease (CKD) stages I — V were . Methods. 70 patients (30 male, 40 female) with CKD stages I — V (mean age 41±6,7 years) were included into the study. Signs of target organ damage, serum concentrations of FGF23/Klotho were determined. Results. Serum concentration of FGF23/Klotho was associated with serum C-reactive protein level (r = (+)0,370, p<0,01 and r = (-) 0,453, p<001), nutritive status ( r = (+)0,559, p<0,01 and r = (-)0,581, p<0,01) and proteinuria (r = (+)0,305, p<0,05 and r = (-)0,502,p<0,01). Coefficient FGF-23/Klotho correlates with anemia severity. Conclusion. Determination of FGF23/Klotho can be used for determination of prognosis of CKD.

Full Text

Restricted Access

References

  1. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am. J. Kidney Dis. 2003; 41:11-17.
  2. Hruska K.A., Mathew S., Lund R. Hyperphosphatemia of Chronic Kidney Disease Kidney Int. 2008;74(2): 148-157.
  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl. 113): S1-S130.
  4. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010). Нефрол. и диал. 2011; 13(1): 33-51.
  5. Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Am. J. Soc. Nephrol. 2005; 16: 2205-2215.
  6. Chung-Yi C., Makoto K., Mohammed S. Razzaque Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23-Klotho System: Adv Chronic Kidney Dis. 2011; 18(2): 91-97.
  7. Hu M.C., Shi M., Zhang J. et al. Klotho deficiency causes vascular calcification in chronic kidney disease. Am. J. Soc. Nephrol. 2011; 22(1): 124-136.
  8. Hu P., Xuan Q., Hu B. et al. Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease. Biol. J. Sci. 2012;8(5): 663-671.
  9. Makoto Kuro-O. Klotho in chronic kidney disease - What's new? Nephrology Dialysis Transplant. 2009; 24(6): 1705-1708.
  10. Semba R.D., Cappola A.R., Sun K. et al. Plasma klotho and cardiovascular disease in adults. Am. J. Geriatr. Soc. 2011;59(9):1596-1601.
  11. Maltese G., Karalliedde J. The Putative Role of the Antiageing Protein Klotho in Cardiovascular and Renal Disease. Int. J. Hypertens. 2012; 2012: 757469
  12. Martin A., David V., Quarles L.D. Regulation and function of the FGF23/ KLOTHO endocrine pathways. Physiol Rev. 2012;92(1):131-155.
  13. Cavalli L., Mazzotta C., Brandi M.L. Phosphatonins: physiological role and pathological changes. Clin. Cases. Miner. Bone Metab. 2012;9(1):9-12.
  14. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH. 2012;95-118.
  15. Шутов Е.В. Значение фактора роста фибробластов-23 у больных хронической болезнью почек - обзор современных исследований. Лечащий врач. 2012;8:12-18.
  16. Kuro-o M., Matsumura Y., Aizawa H. et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390 (6655): 45-51.
  17. Добронравов В.А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология. 2011;15(4):11-20.
  18. Matsumura Y., Aizawa H., Shiraki-Iida T. et al. Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochemical and Biophysical Research Communications. 1998;242(3):626-630.
  19. Gutiérrez O.M., Januzzi J.L., Isakova T. et al. Fibroblast Growth Factor-23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation. 2009;119(19):2545-2552.
  20. Isakova T., Wahl P., Vargas G.S. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-78.
  21. Haruna Y., Kashihara N., Satoh M. et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(7):2331-2336.
  22. Hu M.C., Shi M., Zhang J. et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney International. 2010; 78(12): 1240-1251.
  23. Sugiura H., Yoshida T., Tsuchiya K. et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant. 2005; 20(12): 2636-2645.
  24. Sugiura H., Yoshida T., Mitobe M. et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol. Dial. Transplant. 2010;25(1):60-68.
  25. Aizawa H., Saito Y., Nakamura T. et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochemical and Biophysical Research Communications. 1998;249(3):865-871.
  26. Wang Y., Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension. 2009; 54(4): 810-817.
  27. Doi S., Zou Y., Togao O. et al. Klotho inhibits transforming growth factor-β1 (TGF-ß1) signaling and suppresses renal fibrosis and cancer metastasis in mice. Biol. J. Chem. 2011;286(10):8655-8665.
  28. Mirza M.A., Larsson A., Lind L. et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-390.
  29. Maekawa Y., Ishikawa K., Yasuda O. et al. Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-χB activation. Endocrine. 2009; 35(3): 341-346.
  30. Mitani H., Ishizaka N., Aizawa T. et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39: 838-843.
  31. Borst M.H., Vervloet M.G. Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease. Am. J. Soc. Nephrol. 2011; 22(9): 1603-1609.
  32. Wang Y., Sun Z. Klotho Gene Delivery Prevents the Progression of Spontaneous Hypertension and Renal Damage. Hypertension 2009; 54: 810-817.
  33. Saito Y., Nakamura T., Ohyama Y. et al. In vivo Klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun. 2000; 276(2): 767-772.
  34. Koh N., Fujimori T., Nishiguchi S. et al. Severely reduced production of Klotho in human chronic renal failure kidney. Biochemical and Biophysical Research Communications. 2001; 280(4): 1015-1020.
  35. Faul C., Amaral A.P., Oskouei B. et al. FGF23 induces left ventricular hypertrophy. Clin. J. Invest. 2011; 121: 4393-408.
  36. Budoff M.J., Rader M.P. et al. Relationship of Estimated GFR and Coronary Artery Calcification in the (CRIC) Chronic Renal Insufficiency Cohort Study. Am. J. Kidney Dis. 2011; 58(4): 519-526.
  37. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin. Dial. 2003; 16(2): 101-105.
  38. Милованова Л.Ю., Козловская Л.В., Милованов Ю.С. и др. Механизмы нарушения фофсорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и klotho. Тер. арх. 2010; 6: 66-72.
  39. Middleton R.J., Parfrey P.S., Foley R.N. Left ventricular hypertrophy in the renal patient. Am. J. Soc. Nephrol. 2001; 12:1079-84.
  40. Gutiérrez O.M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-592.
  41. Милованова Л.Ю., Милованов Ю.С., Плотникова А.А. и др. Эктопическая минерализация при хронической болезни почек - механизмы, патогенез, современные возможности профилактики и лечения. Современ. мед. наука. 2012; 1: 16-33.
  42. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III-V стадий. Клин. нефрол. 2011; 1: 58-68.
  43. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-соудистых заболеваний у больных ХПН. Нефрол. и диал. 2002; 2:113-117.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies